Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: EYLEA Clear all

Conditions: Radiation Retinopathy
Interventions: Aflibercept; Drug
Lead sponsor: Amy C Schefler, MD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Houston, Texas • Katy, Texas • The Woodlands, Texas

Conditions: Neovascular Age-related Macular Degeneration
Interventions: 2.0 mg OPT-302, 2.0 aflibercept, Sham; Biological · Procedure
Lead sponsor: Opthea Limited; Industry
Eligibility: 50 Years and older
Enrollment: 998 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 60
States / cities: Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 57 more

Conditions: Diabetic Macular Edema
Interventions: MYL-1701P, Eylea; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 13
States / cities: Phoenix, Arizona • Sacramento, California • St. Petersburg, Florida + 9 more

Conditions: Diabetic Macular Edema
Interventions: Ranibizumab 0.3 mg, Aflibercept 2.0 mg; Drug
Lead sponsor: Arshad Khanani; Other
Eligibility: 21 Years and older
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Wet Age-related Macular Degeneration
Interventions: EYP-1901, Aflibercept 2mg/0.05mL Inj,Oph; Drug
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 67
States / cities: Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 64 more

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: 4 mg CLS-TA, Sham, IVT aflibercept; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more

Conditions: Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma, Ovarian Sarcoma, Recurrent Ovarian Epithelial Cancer, Recurrent Uterine Sarcoma, Stage III Ovarian Epithelial Cancer, Stage III Uterine Sarcoma, Stage IV Ovarian Epithelial Cancer, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma
Interventions: ziv-aflibercept; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 8
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 5 more

Conditions: Ovarian Neoplasms, Ascites
Interventions: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Neovascular Age-related Macular Degeneration
Interventions: OTX-TKI, Aflibercept; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 84
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 73 more

Conditions: Macular Edema Secondary to Retinal Vein Occlusion
Interventions: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein; Drug · Diagnostic Test
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Fullerton, California • Long Beach, California • Mountain View, California + 48 more

Conditions: Diabetic Macular Edema
Interventions: IVT Aflibercept, SC CLS-TA; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Mountain View, California • The Woodlands, Texas

Conditions: Branch Retinal Vein Occlusion
Interventions: Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321); Procedure · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Intravitreal Aflibercept Injection 2mg; Drug
Lead sponsor: Tennessee Retina; Other
Eligibility: 50 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetic Retinopathy, DR
Interventions: Standard of Care, Aflibercept; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Not listed
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 20
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 17 more

Conditions: Neovascular (Wet) Age-related Macular Degeneration (AMD)
Interventions: ABP 938, Aflibercept; Drug
Lead sponsor: Amgen; Industry
Eligibility: 50 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 41
States / cities: Phoenix, Arizona • Fullerton, California • La Jolla, California + 36 more

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: Ranibizumab 0.5mg, Aflibercept 2.0mg; Drug
Lead sponsor: Arshad Khanani; Other
Eligibility: 65 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions: ADVM-022; Biological
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 9
States / cities: Bakersfield, California • Beverly Hills, California • Lakewood, Colorado + 6 more

Conditions: Diabetic Retinopathy, Macular Edema
Interventions: MK-8748, Aflibercept; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 26
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 23 more

Conditions: Diabetic Macular Edema
Interventions: Aflibercept, Focal Laser; Drug · Procedure
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Houston, Texas • Katy, Texas • The Woodlands, Texas

Conditions: Age-related Macular Degeneration (AMD)
Interventions: Aflibercept, Ranibizumab, Bevacizumab; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 331,541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Neovascular Age-related Macular Degeneration
Interventions: ADVM-022; Genetic
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 34
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more

Conditions: Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
Interventions: Remigromig, Aflibercept 2.0 mg; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 55
States / cities: Scottsdale, Arizona • Glendale, California • Modesto, California + 34 more

Conditions: Proliferative Diabetic Retinopathy
Interventions: Aflibercept, Endolaserless Vitrectomy; Drug · Procedure
Lead sponsor: Southeast Retina Center, Georgia; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 81
States / cities: Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more

Search by objective public record fields.

Intravitreal Aflibercept Injection for Radiation Retinopathy Trial

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)

Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)

Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]

A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO

Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)